Inflammation

Items 11-20 of 29

Page
per page
Set Descending Direction
  1. anti-Netrin-1 (human), mAb (rec.) (blocking) (2F5) (preservative-free)
    AG-27B-0018PF
    AG-27B-0018PF-C100100 µg
    CHF 420.00
    AG-27B-0018PF-C500500 µg
    CHF 1'140.00
    Schematic antibody structure of the recombinant antibody anti-Netrin-1 (human), mAb (rec.) (blocking) (2F5) (Prod. No. AG-27B-0018PF). The single chain variable human fragment (ScFv) selected by antibody phage display technology and specific to the antige
  2. anti-Netrin-1 (human), mAb (rec.) (H4) (preservative-free)
    AG-27B-0020PF
    AG-27B-0020PF-C100100 µg
    CHF 360.00
    AG-27B-0020PF-C500500 µg
    CHF 1'020.00
    Schematic antibody structure of the recombinant antibody anti-Netrin-1 (human), mAb (rec.) (H4) (Prod. No. AG-27B-0020PF). The single chain variable human fragment (ScFv) selected by antibody phage display technology and specific to the antigen of interes
  3. CD38 (human) (rec.) (His) (active) (10µg)
    BBL-2275
    BBL-2275-C01010 µg
    CHF 782.00
    CD38 (human) (rec.) (His) (active) (10µg)
  4. CD40 (human):Fc (human) (rec.)
    AG-40B-0083
    AG-40B-0083-C05050 µg
    CHF 300.00
    AG-40B-0083-30503 x 50 µg
    CHF 600.00
  5. DR6 (human):Fc (human) (rec)
    AG-40B-0011
    AG-40B-0011-C05050 µg
    CHF 170.00
    AG-40B-0011-30503 x 50 µg
    CHF 335.00
  6. Fas (human):Fc (human) (rec.)
    AG-40B-0082
    AG-40B-0082-C05050 µg
    CHF 300.00
    AG-40B-0082-30503 x 50 µg
    CHF 600.00
  7. FasL (human) (multimeric) (rec.)
    AG-40B-0130
    AG-40B-0130-C01010 µg
    CHF 380.00
    AG-40B-0130-30103 x 10 µg
    CHF 760.00
    Oligomerisation of FasL (h) efficiently triggers Jurkat cell death.Method: Jurkat cells were treated O/N with the indicated concentrations of FasL (human) (multimeric) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Prod. No.
  8. Fc (human):FasL, Soluble (human) (rec.)
    AG-40B-0132
    AG-40B-0132-C01010 µg
    CHF 335.00
    AG-40B-0132-30103 x 10 µg
    CHF 670.00
    Oligomerisation of FasL (h) efficiently triggers Jurkat cell death.Method: Jurkat cells were treated O/N with the indicated concentrations of MegaFasL, Soluble (human) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Pr
  9. IL-2 (C145S Mutant) (human) (rec.) (His)
    CHI-HF-20102
    CHI-HF-20102-C01010 µg
    CHF 210.00
  10. IL-2 (human) (rec.) (untagged)
    CHI-HR-20602
    CHI-HR-20602-C01010 µg
    CHF 170.00

Items 11-20 of 29

Page
per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.